Gastrazole (Rabeprazole)

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Gastrazole (Rabeprazole)

Property Description
Active ingredient Rabeprazole sodium
Form Delayed-release tablets (Enteric-coated)
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Powerful reduction of stomach acid
Origin Synthetic substituted benzimidazole

Gastrazole is a highly specialized, synthetic antisecretory agent used to provide powerful and sustained reduction of stomach acid. It contains the active ingredient Rabeprazole sodium and is classified as a Proton Pump Inhibitor (PPI), which is categorized as its official pharmacological class.


What Type of Medicine is Gastrazole (Rabeprazole)?

Gastrazole contains the active substance Rabeprazole sodium, which is structurally a substituted benzimidazole compound. It belongs to the class of Proton Pump Inhibitors (PPIs), a category of highly effective acid-suppressing agents. Rabeprazole, like other PPIs, is used for achieving profound and prolonged acid suppression in the stomach. This means the medicine provides a consistent reduction in the production of hydrochloric acid (HCl).

Composition and Delivery Form of Gastrazole

Gastrazole is a single active substance product intended for oral administration, typically manufactured as delayed-release tablets or enteric-coated tablets. This specific formulation is critical because the active ingredient, Rabeprazole, is sensitive to acid. The enteric coating protects the drug as it passes through the stomach, ensuring that the Rabeprazole sodium is not degraded by acid before it can be properly absorbed in the small intestine. This controlled delivery ensures the medicine reaches its site of action intact, maximizing its therapeutic effect.

General Purpose and Benefit of Rabeprazole

The primary purpose of Rabeprazole is to provide powerful, prolonged reduction in stomach acidity over the course of the day. This is achieved by the drug's key action: it blocks the function of the proton pump—the enzyme responsible for pumping acid into the stomach. The inhibitory mechanism helps sustain low acid levels. This mechanism provides the comprehensive antisecretory effect needed to help relieve acid-related symptoms, such as the frequent, severe heartburn associated with acid reflux, and allows damaged tissues to begin the natural healing process.

Regulatory References

  1. MedlinePlus
Advertisements

What side effects are possible with Gastrazole (Rabeprazole)?

Possible side effects and safety information

The official safety profile for Gastrazole (Rabeprazole) classifies potential adverse reactions based on their expected frequency and the body system affected, strictly following regulatory standards.

Adverse Reaction Scope

Classification Examples of Officially Documented Adverse Reactions
Common (Affecting 1 to 10 in 100) Headache, Diarrhea, Nausea, Abdominal pain, Flatulence, Constipation, Pain (non-specific), Infection, Pharyngitis, Asthenia.
Uncommon (Affecting 1 to 10 in 1,000) Insomnia, Dizziness, Somnolence, Cough, Rhinitis, Rash, Urticaria, Myalgia, Arthralgia.
Rare (Affecting 1 to 10 in 10,000) Hypersensitivity reactions (including anaphylactic shock), Blood disorders (e.g., Neutropenia), Depression, Vision disturbance.

These reactions are grouped into System-Organ Classes including Gastrointestinal, Nervous System, Skin and Subcutaneous Tissue, and Immune System Disorders.

Serious Adverse Reactions and Safety Patterns

Regulatory documents highlight rare but clinically important reactions. These include a potential increased risk of bone fractures of the hip, wrist, or spine and the occurrence of Hypomagnesaemia (low magnesium levels) with prolonged use, typically defined as use for a year or more. Other serious events noted are Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome, and Acute Tubulointerstitial Nephritis. Furthermore, treatment may be associated with an increased risk of certain gastrointestinal infections, such as those caused by Clostridium difficile.

Regulatory Restrictions

Use is contraindicated in patients with a known hypersensitivity to rabeprazole sodium or related substituted benzimidazoles. Caution is advised when initiating treatment in individuals with severe hepatic dysfunction. Symptomatic improvement with Rabeprazole does not preclude the presence of underlying gastric malignancy, a condition that should be excluded prior to long-term therapy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation on Gastrazole (Rabeprazole) overdose indicates that clinical experience with deliberate massive oral overdose is limited. The signs and manifestations observed in documented cases are generally consistent with the known adverse reaction profile of the medicine. No specific severe or life-threatening outcomes are formally detailed following acute, massive ingestion.


When to Seek Urgent Help

In any situation of suspected or confirmed overdose, regulatory authorities mandate that patients seek immediate medical attention and contact emergency services or a poison control center immediately. This action is required following the ingestion of a dose higher than the prescribed amount.


Official Management and Supportive Care

Management of a Rabeprazole overdose is strictly defined as symptomatic and supportive treatment, directed at maintaining vital functions. The official labeling explicitly states that no specific antidote is known for Rabeprazole. Furthermore, due to the drug's extensive protein binding, it is not readily dialyzable from the circulation, meaning dialysis is not an effective means of removal. Hospital monitoring may be required based on the patient’s clinical status, with continued observation for adverse reactions.

Advertisements

Therapeutic Uses of Gastrazole (Rabeprazole)

Understanding the Uses of Gastrazole (Rabeprazole)

Gastrazole, which contains the active ingredient rabeprazole, belongs to a class of medications known as proton pump inhibitors (PPIs). These medications work by reducing the amount of acid produced by the stomach. By lowering gastric acid levels, Gastrazole helps manage several conditions related to the upper gastrointestinal tract.

Gastroesophageal Reflux Disease (GERD)

Gastrazole is primarily used to treat gastroesophageal reflux disease, a condition where stomach acid flows back into the esophagus. This acid reflux can cause a burning sensation in the chest and throat (heartburn) and may lead to irritation of the esophageal lining. Gastrazole is used for:

  • Symptomatic Relief: Reducing the frequency and severity of heartburn and acid regurgitation.
  • Healing of Erosive Esophagitis: Treating the inflammation and sores in the esophagus caused by chronic acid exposure.
  • Maintenance of Healing: Preventing the recurrence of esophageal damage once it has healed.

Peptic Ulcer Disease

Peptic ulcers are open sores that develop on the inside lining of the stomach or the upper part of the small intestine (duodenum). Gastrazole is effective in treating these conditions by creating a less acidic environment, which allows the ulcers to heal. It is utilized for:

  • Duodenal Ulcers: Treating active sores in the first part of the small intestine.
  • Gastric Ulcers: Treating sores located in the stomach lining.

Helicobacter pylori Eradication

In many cases, peptic ulcers are caused by a bacterial infection known as Helicobacter pylori (H. pylori). Gastrazole is often used as part of a combination therapy with specific antibiotics. The role of the rabeprazole is to suppress stomach acid, which increases the effectiveness of the antibiotics in eliminating the bacteria.

Hypersecretory Conditions

Gastrazole is also indicated for the management of rare pathological conditions where the stomach produces excessive amounts of acid. One such condition is Zollinger-Ellison syndrome, where tumors in the pancreas or duodenum stimulate the overproduction of gastric acid. Continuous treatment helps maintain acid levels within a manageable range.

Benefits of Treatment

By effectively suppressing acid production, Gastrazole provides several clinical benefits:

  • Pain Reduction: Alleviating the discomfort associated with acid-related disorders.
  • Tissue Recovery: Facilitating the natural healing process of the gastrointestinal mucosa.
  • Complication Prevention: Reducing the risk of long-term complications such as esophageal strictures or gastrointestinal bleeding associated with untreated ulcers.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastrazole (Rabeprazole)?

The eligibility for Gastrazole is strictly defined by regulatory documents, focusing on patient status, allergies, and specific conditions. Absolute use is prohibited in patients with a known hypersensitivity to rabeprazole, the drug class (substituted benzimidazoles), or those concurrently taking rilpivirine-containing products.


Eligibility by Age and Organ Function

Population Group Eligibility Status (Regulatory Basis)
Adults (ge 18 Years) Approved for all labeled uses.
Adolescents (ge 12 Years) Approved for short-term symptomatic GERD.
Children (lt 1 Year) Not recommended; efficacy not established.
Renal Impairment Permitted; no dosage adjustment required.
Severe Hepatic Impairment Caution should be exercised due to limited study data.

Specific Restrictions

Use is contra-indicated during pregnancy and lactation, based on European regulatory mandates. Treatment should not be initiated until a gastric or esophageal malignancy has been excluded, as Gastrazole may mask symptoms and delay diagnosis. The medicine is otherwise generally permitted for use in geriatric patients.

Advertisements

What should I know about interactions with other medicines?

Gastrazole (Rabeprazole) Interactions with other medicines and products

The interaction profile of Gastrazole is primarily governed by its ability to elevate gastric pH, altering the plasma exposure of co-administered compounds, as well as specific regulatory restrictions.

Formal Restrictions and pH-Dependent Interactions: Co-administration with Rilpivirine-containing products is formally contraindicated by regulatory authorities due to the documented risk of reduced antiviral efficacy. Use with Nelfinavir is also advised to be avoided.

The pH increase may decrease the absorption of compounds that require an acidic environment, including Ketoconazole, Itraconazole, Oral Iron Salts, and certain agents like Erlotinib. Conversely, the bioavailability of Digoxin is documented to be increased due to the altered gastric pH.

Elimination and Monitoring Requirements: The official labeling notes that co-administration with Warfarin has been associated with reports of increased International Normalized Ratio (INR) and prothrombin time, which necessitates clinical monitoring. For high-dose Methotrexate, exposure may be elevated and prolonged, and temporary withdrawal of Rabeprazole may be considered.

Procedural Constraints: To prevent interference with diagnostic results, Rabeprazole treatment must be stopped for at least five days prior to measuring Chromogranin A ( CgA) levels. Studies show no clinically significant interactions with medicines such as Theophylline, Diazepam, or Phenytoin.

Advertisements

Mechanism of Action

How Gastrazole (Rabeprazole) Works

Gastrazole (rabeprazole) functions as a Proton Pump Inhibitor (PPI), interfering with the final molecular step of gastric acid production. The compound is administered as an inactive prodrug and is selectively transported to the highly acidic secretory canaliculi of the gastric parietal cells.

Targeting the H^+/K^+-ATPase Enzyme

Within this acidic environment, the prodrug undergoes chemical activation, converting into its biologically active sulfonamide form. This active metabolite then forms an irreversible covalent bond with exposed cysteine residues on the hydrogen-potassium-adenosine triphosphatase (H^+/K^+-ATPase) enzyme . This enzyme, the proton pump, is the final common pathway for transporting hydrogen ions (H^+) into the stomach lumen.

Limiting Gastric Acid Secretion

By irreversibly blocking the proton pump, Gastrazole directly limits the transport of H^+ and suppresses the formation of hydrochloric acid (HCl). The cessation of transport activity is sustained because the parietal cell must synthesize and insert new pump molecules into the membrane to restore full secretory function, resulting in a prolonged reduction of hydrogen ion secretion.

Advertisements

Dosage and Administration Information

How Gastrazole (Rabeprazole) is Used

The administration of Gastrazole (Rabeprazole) is governed by specific instructions to ensure the medicine is used correctly. The primary route of administration is oral, with the drug typically manufactured as a delayed-release tablet. For all standard indications, the tablets must be swallowed whole and must not be chewed, crushed, or split to protect the integrity of the enteric coating.

Official Dosing and Scheduling

Rabeprazole is most commonly dosed at 20 mg once daily for the short-term treatment of conditions like erosive GERD (for up to 8 weeks) or symptomatic GERD (for up to 4 weeks). In certain protocols, such as the 7-day H. pylori eradication regimen, the dose is prescribed as 20 mg twice daily as part of a multi-drug course. For pathological hypersecretory conditions like Zollinger-Ellison Syndrome, the starting dose is typically 60 mg once daily, which may be adjusted to divided doses up to a total of 120 mg per day.

Contextual Administration Instructions

The timing of the dose in relation to meals is specified for certain uses. For H. pylori eradication, the drug is taken with both the morning and evening meals. When used for healing duodenal ulcers, the dose is taken after the morning meal. For most other indications, the medicine may be taken with or without food. No dose adjustment is generally required for older adults or patients with mild to moderate kidney or liver impairment. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Findings

Research has explored whether this drug, when administered alongside a lifestyle modification program, is associated with changes in variables related to Type-2 Diabetes Mellitus (T2DM).

  • One study reported that participants receiving the drug measured an average reduction in HbA1c of 1.5% over 12 weeks.
  • The study also included a control group that received the current standard of care.

Research has examined whether the timing of drug administration influenced measured variables.


Associated Clinical Outcomes

A follow-up trial explored whether the combination therapy was associated with changes in patient quality of life after 24 weeks. Data collected included self-reported questionnaires on mobility and general well-being.

Studies have evaluated the agent in patient cohorts with mild renal impairment.

Research has investigated whether the drug was associated with changes in the incidence of major adverse cardiovascular events (MACE) in a high-risk population. The findings were published in the Journal of Metabolic Disorders.


Long-Term Monitoring

Ongoing research is investigating the long-term data collection, including tolerance and measured variables, of continuous administration over a five-year period. Evidence remains limited regarding data collected beyond the initial three-year trial period. It is not yet clear whether changes observed in short-term studies persist over a longer duration.

Key Studies & References

  1. To Determine the Effect of Oral Pantoprazole and Rabeprazole on Blood Glucose Levels in Type 2 Diabetes Mellitus (Informed the 12-week time frame and T2DM focus)
  2. A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients (Informed MACE association and high-risk population investigation)
  3. Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan (Informed Quality of Life exploration and measured variables)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gastrazole (Rabeprazole) (FAQ)

Q: What is the main difference between Gastrazole and other acid-reducing medicines?

Gastrazole ( Rabeprazole) belongs to a specific class of medicines called Proton Pump Inhibitors ( PPIs). Official documents describe this class as working by irreversibly blocking the final molecular step of acid production in the stomach. This mechanism is distinct from other classes of acid reducers, such as H2 receptor blockers, which work on an earlier step.


Q: Does Gastrazole treat only the symptoms or the cause of reflux?

Official indications state that Gastrazole ( Rabeprazole) is used both for the treatment of symptomatic GERD (relieving symptoms like heartburn) and for the healing of erosive or ulcerative forms of GERD. This means the medicine is used for both relieving the discomfort and helping to heal any damage caused by the acid.


Q: Can Gastrazole be taken long-term?

Rabeprazole is indicated for the long-term maintenance of healing in certain forms of reflux disease, studied for up to 12 months, and for treating conditions like Zollinger-Ellison Syndrome. However, official warnings advise using the lowest effective dose for the shortest duration appropriate for the condition associated with certain long-term safety considerations.


Q: What are the most common reasons a doctor prescribes Rabeprazole?

Rabeprazole is officially indicated for several uses based on clinical studies. These include the short-term and maintenance healing of erosive or ulcerative GERD, the short-term treatment of symptomatic GERD, the healing of duodenal ulcers, and as part of a multi-drug course for H. pylori eradication.


Q: How quickly should I expect Gastrazole to start working?

Studies and official data indicate that the process of acid suppression can begin after the first dose of the medicine, supporting observations that acid reduction can begin soon after the first dose.


Q: Does Gastrazole affect vitamin B12 levels?

Official warnings note that daily long-term use of Rabeprazole (typically longer than 3 years) may be associated with a risk of malabsorption or deficiency of Vitamin B12 (cyanocobalamin). This is a consideration for prolonged treatment.


Q: Are there any known issues with taking Gastrazole and blood thinners at the same time?

Official sources note that taking Rabeprazole concurrently with the blood thinner warfarin may result in an increased risk of bleeding. If these two medicines are taken together, official sources indicate that close monitoring of INR (International Normalized Ratio) and prothrombin time may be necessary.


Q: Can Gastrazole cause bone issues if used for a long time?

Official warnings indicate that long-term and multiple daily dose use of Rabeprazole may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. This concern is generally associated with prolonged use (a year or longer) and/or use of multiple daily doses.


Q: Can Gastrazole be taken during pregnancy?

There are no adequate and well-controlled studies of Gastrazole ( Rabeprazole) use in pregnant women. It is generally recommended that the medicine be used during pregnancy only if the potential benefit to the mother justifies the potential risk, as determined by the potential benefit and risk assessment.


Q: Is it okay to take Gastrazole if I have liver problems?

Dose adjustment is not typically necessary for patients with mild to moderate liver problems. However, official data shows that use in patients with severe liver impairment has not been extensively studied in clinical trials, and monitoring may be necessary in such cases.


Q: Does taking Rabeprazole make me more susceptible to certain infections?

Official warnings mention that Rabeprazole, like other medicines in its class, may be associated with an increased risk of a severe type of diarrhea called Clostridium difficile associated diarrhea ( CDAD). General 'infection' is also listed as a common adverse reaction in clinical studies.


Q: Is Gastrazole the same as omeprazole, or are they different?

Gastrazole ( Rabeprazole) and omeprazole are both categorized in the same class of medicines: Proton Pump Inhibitors ( PPIs). They share the same mechanism of action by blocking the final step of acid secretion. However, they are chemically distinct compounds.


Q: Why does Gastrazole sometimes cause headaches?

Headache is listed in the official prescribing information as one of the most common adverse reactions reported in clinical studies of Rabeprazole. It has been reported in both adult and adolescent patients using the medicine.


Q: What is the typical time frame Gastrazole is used for GERD?

For the short-term treatment of symptomatic GERD (heartburn), the typical use period is up to 4 weeks. For the healing of erosive or ulcerative GERD (damage to the esophagus), the treatment period is typically 4 to 8 weeks, according to official data.


Q: Can Gastrazole affect the absorption of other medications?

Yes, Rabeprazole works by reducing stomach acid, and this reduction in stomach acidity may interfere with the absorption of other medicines. This primarily affects those drugs that rely on a specific gastric pH (acidity level) to be properly absorbed, such as certain antifungal medicines or iron salts.


Q: Is it safe to drink alcohol while taking Gastrazole?

Official regulatory sources do not list a specific contraindication or interaction between Gastrazole ( Rabeprazole) and alcohol that requires specific monitoring.


Q: Does Gastrazole interact with antacids?

Clinical trials and specific drug-drug interaction studies mentioned in official prescribing information found no specific interaction when Gastrazole ( Rabeprazole) was taken at the same time as liquid antacids.


Q: Can I stop taking Gastrazole suddenly?

Official documents for Rabeprazole mention studies involving treatment withdrawal evaluation. For patients taking the medicine for long periods, the process of stopping the medication often requires monitoring.


Q: Is there a maximum amount of time Gastrazole is generally recommended for?

For most common indications, the typical use period is short-term. While some conditions are treated long-term, official warnings emphasize using the lowest effective dose for the shortest duration appropriate for the condition, rather than a fixed maximum time limit for everyone.


Q: Are children allowed to take Gastrazole?

Yes, Rabeprazole is indicated for the treatment of GERD in adolescent patients 12 years of age and older and in pediatric patients 1 to 11 years of age. Use is not recommended for children under 1 year old.


Q: What research evidence supports the use of Gastrazole for heartburn?

Official documents list the treatment of symptomatic GERD (which includes heartburn) as an approved indication. This approval is based on controlled clinical studies that demonstrated the medicine's efficacy over a placebo in reducing these symptoms.


Q: Why is Gastrazole sometimes taken only for a short course?

Rabeprazole is frequently prescribed for short courses because its official indications include the short-term treatment of symptomatic GERD (up to 4 weeks) and the short-term healing of erosive GERD (4 to 8 weeks). Once the acute phase of the condition is managed, the course of treatment may be complete.


Q: What is the difference between Gastrazole and H2 blockers?

Gastrazole ( Rabeprazole) is a Proton Pump Inhibitor ( PPI), meaning it works by blocking the final common step of acid production. This differs from H2 receptor blockers, which work at a different site to reduce the signal that causes acid secretion.


Q: Can seniors use Gastrazole?

Official data indicates that Rabeprazole's metabolism is not significantly affected by advanced age. Therefore, a general dose adjustment is usually not required for older adults.


Q: Can Gastrazole cause magnesium levels to drop?

Official warnings indicate that low magnesium levels (hypomagnesemia) have been reported rarely with the use of PPIs, including Rabeprazole. This is generally associated with prolonged treatment, often lasting more than a year.


Q: What should I do if I notice unusual side effects while on Gastrazole?

Official prescribing information advises reporting suspected adverse reactions to a healthcare professional and the regulating body (such as the FDA in the U.S.) through their official reporting programs.


Q: Does Gastrazole affect kidney function?

Official warnings note that a kidney condition called acute interstitial nephritis has been observed in patients taking medicines in this class, including Rabeprazole. This can occur at any point during treatment, and the medicine should be discontinued if it develops.


Q: What are the signs of a serious allergic reaction to Rabeprazole?

Official sources note that hypersensitivity reactions may occur. Signs of such a serious reaction can include sudden swelling of the face, tongue, or throat (angioedema), severe trouble breathing (bronchospasm), and a severe systemic reaction called anaphylaxis.


Q: Is Gastrazole a prescription-only medicine?

Gastrazole ( Rabeprazole) is designated by the regulating body as a prescription-only medicine. This means it is only available with a valid prescription from a licensed healthcare provider.


Q: Do official sources discuss the possibility of Rabeprazole needing to be slowly stopped?

Official clinical trial documents mention studies that include a 'treatment withdrawal evaluation.' This finding indicates that the process of stopping the medication may require management.


Q: How does Gastrazole relate to acid rebound after stopping treatment?

Research designs cited in official documents include evaluation of patient symptoms following treatment withdrawal. This type of monitoring is used to observe the return of acid symptoms that can occur after the cessation of acid-suppressing therapy.


Q: What are the general guidelines for who should avoid Gastrazole?

Gastrazole ( Rabeprazole) is contraindicated (should be avoided) in individuals with a known hypersensitivity (allergy) to the medicine itself, to any component of the formulation, or to other medicines in the same class ( PPIs). It is also contraindicated for use with certain other medicines, such as those containing rilpivirine.


Q: Is Rabeprazole safe for use while breastfeeding?

Official sources state that Rabeprazole is expected to be excreted in human milk, but the effects on the breastfed infant are currently unknown. It is generally recommended that the importance of the medicine to the mother be weighed against the potential risk to the infant.


Q: What is the role of Gastrazole in healing damaged esophagus?

Rabeprazole is officially indicated for the healing of erosive or ulcerative Gastroesophageal Reflux Disease ( GERD). This indication means it is used to help repair the damage and ulcers that may be present on the lining of the esophagus due to acid exposure.


Q: Can I take Gastrazole if I have lactose intolerance?

Many forms of Rabeprazole contain lactose as an inactive ingredient. The official document listing inactive ingredients should be checked for the specific product formulation prescribed to verify the presence of lactose.


Q: Does Gastrazole need to be taken with food?

For most prescribed uses, Gastrazole ( Rabeprazole) may be taken with or without food. However, for certain conditions, such as treating H. pylori or duodenal ulcers, official instructions specify taking the medicine with or after a meal.


Q: How long does the effect of one dose of Gastrazole usually last?

The medicine works by irreversibly blocking the acid pump, which causes a prolonged effect. Studies and official information indicate that a dose of Rabeprazole can suppress acid production for approximately 24 to 48 hours until the stomach cells create new acid pumps.


Q: What is Zollinger-Ellison syndrome, and why is Gastrazole used to treat it?

Zollinger-Ellison syndrome ( ZES) is described in official sources as a pathological hypersecretory condition where the stomach produces excessive acid. Gastrazole ( Rabeprazole) is indicated for the long-term treatment of ZES to help control this high acid production.

Advertisements

How should Gastrazole (Rabeprazole) be stored and disposed of?

Storage Requirements for Gastrazole (Rabeprazole)

Gastrazole (rabeprazole sodium) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container with the lid tightly closed and protected from excess heat and moisture. The official labeling requires that the product be kept securely out of reach of children at all times.

Storage Restriction Requirement
Temperature Controlled Room Temperature (20 C–25 C)
Container Original container, tightly closed
Stability (Sprinkles) Must be taken within 15 minutes of preparation

Disposal of Unused Product

Unused or expired rabeprazole must be disposed of according to official guidelines and local regulations. The preferred method is to utilize a drug take-back option, such as a collection site or mail-back program. If a take-back program is unavailable, the medication should be prepared for disposal in the household trash, as rabeprazole is not included on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrazole (Rabeprazole) found in:

A-Z Index: